CY1120552T1 - Ενωση εστερα γουανιδινοβενζοϊκου οξεος - Google Patents

Ενωση εστερα γουανιδινοβενζοϊκου οξεος

Info

Publication number
CY1120552T1
CY1120552T1 CY20181100832T CY181100832T CY1120552T1 CY 1120552 T1 CY1120552 T1 CY 1120552T1 CY 20181100832 T CY20181100832 T CY 20181100832T CY 181100832 T CY181100832 T CY 181100832T CY 1120552 T1 CY1120552 T1 CY 1120552T1
Authority
CY
Cyprus
Prior art keywords
agent
prevention
treatment
guanidinobenzoic acid
present
Prior art date
Application number
CY20181100832T
Other languages
English (en)
Inventor
Jiro Fujiyasu
Toru Asano
Susumu Yamaki
Osamu Kaneko
Yuka KOIKE
Tomoyoshi IMAIZUMI
Yasuharu Urano
Tomohki SATOU
Satoshi Sasamura
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1120552T1 publication Critical patent/CY1120552T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

[Πρόβλημα] Η παροχή μιας ένωσης η οποία είναι χρήσιμη ως ένας παράγοντας για την πρόληψη ή/και θεραπεία νεφρικών νόσων. [Μέσα για την Επίλυση] Οι εφευρέτες της παρούσας μελέτησαν ενώσεις που έχουν μια ανασταλτική της θρυψίνης δραστικότητα, και επιβεβαίωσαν ότι μια ένωση εστέρα γουανιδινοβενζοϊκού οξέος έχει μια ανασταλτική της θρυψίνης δραστικότητα, περατώνοντας έτσι την παρούσα εφεύρεση. Η ένωση εστέρα γουανιδινοβενζοϊκού οξέος της παρούσας εφεύρεσης μπορεί να χρησιμοποιηθεί ως ένας παράγοντας για την πρόληψη ή/και θεραπεία νεφρικών νόσων (για παράδειγμα, χρόνιας νεφρικής νόσου, οξείας σπειραματονεφρίτιδας, οξείας νεφρικής βλάβης, και τα παρόμοια) ως ένας παράγοντας ο οποίος θα υποκαταστήσει τη θεραπεία με δίαιτα χαμηλής περιεκτικότητας σε πρωτεΐνες, ή/και ως ένας παράγοντας για την πρόληψη ή/και θεραπεία σχετιζόμενων με τη θρυψίνη νόσων (για παράδειγμα, χρόνιας παγκρεατίτιδας, νόσου γαστροοισοφαγικής παλινδρόμησης, ηπατικής εγκεφαλοπάθειας. γρίπης, και τα παρόμοια).
CY20181100832T 2013-03-13 2018-08-09 Ενωση εστερα γουανιδινοβενζοϊκου οξεος CY1120552T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013050011 2013-03-13
PCT/JP2014/056601 WO2014142219A1 (ja) 2013-03-13 2014-03-13 グアニジノ安息香酸エステル化合物

Publications (1)

Publication Number Publication Date
CY1120552T1 true CY1120552T1 (el) 2019-07-10

Family

ID=51536870

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100832T CY1120552T1 (el) 2013-03-13 2018-08-09 Ενωση εστερα γουανιδινοβενζοϊκου οξεος

Country Status (30)

Country Link
US (1) US9969709B2 (el)
EP (1) EP2975023B1 (el)
JP (1) JP6314129B2 (el)
KR (1) KR102145649B1 (el)
CN (1) CN105051008B (el)
AU (1) AU2014230583B2 (el)
BR (1) BR112015022762B1 (el)
CA (1) CA2905606C (el)
CY (1) CY1120552T1 (el)
DK (1) DK2975023T3 (el)
ES (1) ES2684045T3 (el)
HK (1) HK1216246A1 (el)
HR (1) HRP20181371T1 (el)
HU (1) HUE039526T2 (el)
IL (1) IL241541B (el)
LT (1) LT2975023T (el)
MX (1) MX2015012604A (el)
MY (1) MY194604A (el)
PH (1) PH12015502023A1 (el)
PL (1) PL2975023T3 (el)
PT (1) PT2975023T (el)
RS (1) RS57568B1 (el)
RU (1) RU2661895C2 (el)
SG (2) SG10201707504VA (el)
SI (1) SI2975023T1 (el)
TR (1) TR201809418T4 (el)
TW (1) TWI666196B (el)
UA (1) UA118668C2 (el)
WO (1) WO2014142219A1 (el)
ZA (1) ZA201506745B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022762B1 (pt) 2013-03-13 2022-08-16 Takeda Pharmaceutical Company Limited Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
US10017487B2 (en) * 2015-03-27 2018-07-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN105218289B (zh) * 2015-10-15 2017-08-01 浙江大学 一种不饱和脂肪酸原位加氢脱羧制备长链烷烃的方法
CA3081564A1 (en) 2017-11-02 2019-05-09 Ube Industries, Ltd. Double-headed protease inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
WO1994013631A1 (en) 1992-12-10 1994-06-23 Teikoku Chemical Industries Co., Ltd. Propionic acid derivative
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
JPH09124571A (ja) 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
WO1997037969A1 (fr) 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Inhibiteur de tryptase derives de guanidino
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターｄ阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja) * 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
US7671057B2 (en) 2004-11-08 2010-03-02 Ono Pharmaceutical Co., Ltd. Therapeutic agent for type II diabetes comprising protease-inhibiting compound
CA2588087A1 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
US20080274945A1 (en) 2004-11-26 2008-11-06 N.V. Nutricia Infant Nutrition With Protease Inhibitor
JP2008528628A (ja) 2005-01-31 2008-07-31 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性二環式化合物
CA2635210A1 (en) 2006-01-12 2007-08-02 Merck & Co., Inc. Hydroxyalkylarylamide derivatives
CA2707549A1 (en) 2007-12-03 2009-06-11 Itzik Harosh Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
EP2511271B1 (en) 2009-12-07 2015-01-21 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP2725016B1 (en) 2011-06-07 2016-12-21 EA Pharma Co., Ltd. Heterocyclic carboxylic acid ester derivative
WO2013039187A1 (ja) 2011-09-15 2013-03-21 アステラス製薬株式会社 グアニジノ安息香酸化合物
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
JP2016505613A (ja) 2013-01-03 2016-02-25 オラムド エルティーディー． Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
SG11201507196WA (en) 2013-03-08 2015-10-29 Amgen Inc Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
BR112015022762B1 (pt) 2013-03-13 2022-08-16 Takeda Pharmaceutical Company Limited Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound

Also Published As

Publication number Publication date
PT2975023T (pt) 2018-07-27
TW201522291A (zh) 2015-06-16
US20160031847A1 (en) 2016-02-04
AU2014230583B2 (en) 2017-09-28
WO2014142219A1 (ja) 2014-09-18
ZA201506745B (en) 2017-04-26
TWI666196B (zh) 2019-07-21
HK1216246A1 (zh) 2016-10-28
ES2684045T3 (es) 2018-10-01
EP2975023B1 (en) 2018-05-30
JPWO2014142219A1 (ja) 2017-02-16
UA118668C2 (uk) 2019-02-25
RU2661895C2 (ru) 2018-07-23
SG10201707504VA (en) 2017-10-30
MX2015012604A (es) 2016-10-13
KR20150130392A (ko) 2015-11-23
RS57568B1 (sr) 2018-10-31
US9969709B2 (en) 2018-05-15
TR201809418T4 (tr) 2018-07-23
AU2014230583A1 (en) 2015-10-01
CA2905606C (en) 2021-03-09
MY194604A (en) 2022-12-06
DK2975023T3 (en) 2018-08-20
HUE039526T2 (hu) 2019-01-28
BR112015022762B1 (pt) 2022-08-16
SI2975023T1 (sl) 2018-10-30
BR112015022762A2 (pt) 2017-07-18
LT2975023T (lt) 2018-08-10
PH12015502023B1 (en) 2016-01-18
PH12015502023A1 (en) 2016-01-18
BR112015022762A8 (pt) 2018-01-23
SG11201507411TA (en) 2015-10-29
PL2975023T3 (pl) 2018-11-30
CN105051008B (zh) 2018-05-29
CA2905606A1 (en) 2014-09-18
CN105051008A (zh) 2015-11-11
RU2015143562A (ru) 2017-04-19
EP2975023A1 (en) 2016-01-20
IL241541B (en) 2019-06-30
KR102145649B1 (ko) 2020-08-18
HRP20181371T1 (hr) 2018-10-19
JP6314129B2 (ja) 2018-04-18
EP2975023A4 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
CY1120552T1 (el) Ενωση εστερα γουανιδινοβενζοϊκου οξεος
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CY1124046T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
EA201691354A1 (ru) Терапевтические ингибирующие соединения
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
EA201490632A1 (ru) Соединение гуанидинобензойной кислоты
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201591339A1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
EA201791576A1 (ru) Ингибитор jak
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
UA111382C2 (uk) Інгібітори протеїнкінази
EA201591509A1 (ru) Ингибиторы cdc7
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
AR094970A1 (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
EA201792471A1 (ru) Бигетероарильные соединения и их применения
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CY1126036T1 (el) Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας
JP2017506627A5 (el)
EA201792021A1 (ru) Ингибитор jak
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου